Overview

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2031-10-01
Target enrollment:
Participant gender:
Summary
To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Bristol-Myers Squibb
Treatments:
130-nm albumin-bound paclitaxel
Gemcitabine